产品
编 号：F350445
分子式：C18H13F6NO4S
分子量：453.36
分子式：C18H13F6NO4S
分子量：453.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 406205-74-1
产品详情
生物活性：
Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively. Bay 59-3074 has analgesic properties.
体内研究：
BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain.Animal Model:Male Wistar rats (160-250 g)
Dosage:0.3 mg/kg, 1 mg/kg, and 3 mg/kg
Administration:Oral administration; daily; for 2 weeks.
Result:Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.
Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively. Bay 59-3074 has analgesic properties.
体内研究：
BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain.Animal Model:Male Wistar rats (160-250 g)
Dosage:0.3 mg/kg, 1 mg/kg, and 3 mg/kg
Administration:Oral administration; daily; for 2 weeks.
Result:Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备